BioEP is a seizure susceptibility assessment technology that can provide objective support to clinicians enabling faster and more accurate diagnosis of epilepsy.
Epilepsy is a serious neurological condition that affects almost 1% of the population at some period during their lives.
BioEP is a seizure susceptibility assessment technology that can enabling faster and more accurate diagnosis of epilepsy.
Neuronostics is now encouraging enquiries from Pharmaceutical companies, EEG hardware and software companies.
Neuronostics is a newly established University of Exeter (UK) spin-out, focused on the development and commercialisation of a novel and potentially revolutionary seizure susceptibility assessment technology called #BioEP.
Our goal at Neuronostics is to improve the quality of life of people with epilepsy, those suspected of having epilepsy and those family and friends who share their lives with them.
We are working in partnership with members of the public, people with epilepsy, special interest groups, researchers, doctors and neurologists, to bring the benefits of #BioEP to the wider community globally.
Neuronostics Ltd, today announces that it has been selected by Microsoft for a new programme designed to help startups get off the ground. Microsoft for Startups will provide up to $500 million worth of... [Read More]
Neuronostics, the developer of #BioEP, the revolutionary epilepsy assessment tool, announces the appointment of Dr. Wessel (Wes) Woldman as Scientific Director. Dr. Woldman, will lead and manage application research and development of... [Read More]
Neuronostics Ltd, developer of the revolutionary seizure susceptibility assessment technology called #BioEP, announces the appointment of Ross Parkman as Technical & Operations Director. Mr Parkman, who previously 15 years at IT solutions... [Read More]